$4.29
3.13%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US6821431029
Symbol
OMER

Omeros Corporation Stock price

$4.29
+0.59 15.79% 1M
-3.88 47.49% 6M
-5.59 56.58% YTD
+0.08 1.90% 1Y
-0.22 4.88% 3Y
-6.27 59.38% 5Y
-9.18 68.15% 10Y
-4.44 50.86% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.13 3.13%
ISIN
US6821431029
Symbol
OMER
Industry

Key metrics

Basic
Market capitalization
$292.0m
Enterprise Value
$636.3m
Net debt
$344.4m
Cash
$28.7m
Shares outstanding
60.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 229.0
EV/Sales
- | 499.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-65.9%
Return on Equity
86.0%
ROCE
-120.3%
ROIC
-
Debt/Equity
-1.6
Financials (TTM | estimate)
Revenue
$0.0 | $1.3m
EBITDA
$-137.4m | $-43.2m
EBIT
$-138.4m | $-141.2m
Net Income
$-122.5m | $-116.0m
Free Cash Flow
$-118.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
24.1% | 74.3%
EBIT
23.9% | 16.5%
Net Income
12.4% | 26.1%
Free Cash Flow
23.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -3,389.6%
EBIT
-
Net
- | -9,099.0%
Free Cash Flow
-
More
EPS
$-2.1
FCF per Share
$-2.0
Short interest
20.5%
Employees
202
Rev per Employee
$0.0
Show more

Is Omeros Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Omeros Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Omeros Corporation forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Omeros Corporation forecast:

Buy
73%
Hold
27%

Financial data from Omeros Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
15% 15%
-
- Research and Development Expense 93 93
30% 30%
-
-137 -137
24% 24%
-
- Depreciation and Amortization 1.03 1.03
27% 27%
-
EBIT (Operating Income) EBIT -138 -138
24% 24%
-
Net Profit -122 -122
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Omeros Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omeros Corporation Stock News

Neutral
Business Wire
about 21 hours ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Narsoplimab inhibits MAS...
Neutral
Seeking Alpha
15 days ago
Omeros Corporation (NASDAQ:OMER ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Catherine A. Melfi - Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems David J.
Neutral
Business Wire
20 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For the six months ended Ju...
More Omeros Corporation News

Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Head office United States
CEO Gregory Demopulos
Employees 202
Founded 1994
Website www.omeros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today